Considerations and Challenges in the Remdesivir COVID-19 Pediatric Development Program

Area of Science:

• Pediatric infectious diseases
• Antiviral drug development
• Regulatory science

Background:

• The U.S. Food and Drug Administration (FDA) sought effective antiviral treatments for pediatric coronavirus disease 2019 (COVID-19).
• Remdesivir (RDV) was previously available under emergency use authorization for certain pediatric populations.
• COVID-19 presents similarly in adults and pediatric patients, suggesting potential efficacy of adult-tested antivirals.

Purpose of the Study:

• To detail the regulatory process and considerations for expanding remdesivir (RDV) indication to pediatric patients.
• To summarize the development program for RDV in treating COVID-19 in neonates, infants, and children.
• To discuss lessons learned from the pediatric RDV development and approval pathway.

Main Methods:

• Review of safety and efficacy data from adult and adolescent Phase 3 trials.
• Analysis of safety and pharmacokinetic data from a Phase 2/3 pediatric clinical trial (53 participants).
• Examination of the evolution of Emergency Use Authorization (EUA) to full FDA approval for pediatric use.

Main Results:

• On April 25, 2022, the FDA approved RDV for hospitalized pediatric patients and non-hospitalized, high-risk pediatric patients (≥28 days old, ≥3 kg) with confirmed SARS-CoV-2 infection.
• The expanded indication was supported by adult trial data and pediatric pharmacokinetic and safety data.
• The FDA simultaneously revoked the prior EUA for RDV in this pediatric population.

Conclusions:

• The FDA's regulatory actions facilitated access to an effective antiviral for pediatric COVID-19.
• The development program highlights the importance of pediatric-specific data alongside adult data for drug approval.
• Key regulatory considerations and lessons learned from the RDV pediatric program can inform future pediatric antiviral development.